Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Neurochir (Wien) ; 163(7): 1867-1871, 2021 07.
Article in English | MEDLINE | ID: mdl-32676689

ABSTRACT

We share our experience with stereotactic gamma knife thalamotomy (GKT) for medically refractory Holmes tremor (HT). A 22-year-old patient underwent gamma knife thalamotomy at ventrointermediate nucleus for disabling HT of the right upper limb. A single 4-mm isocenter was used to target the ventral intermediate nucleus with 130 Gy radiation. At 4 months follow up, we observed 84% improvement in his Fahn-Tolosa-Marin (FTM) rating scale with significant improvement in the right upper limb dystonic tremor. There was only subtle improvement in the ataxic component of the right lower limb. At 1 year after stereotactic GKT, there was sustained neurological improvement with no side effect, We present the stereotactic GKT as a treatment modality for drug-resistant HT. Moreover, it may be considered an alternate treatment modality especially in patients reluctant or contraindicated for any invasive surgical technique. CLINICAL TRIAL REGISTRATION NUMBER: Not required.


Subject(s)
Radiosurgery , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Pharmaceutical Preparations , Thalamus/surgery , Treatment Outcome , Tremor/surgery , Young Adult
2.
Anaerobe ; 61: 102084, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31398389

ABSTRACT

Brain abscess remains a life-threatening condition. Here, we are reporting a case of brain abscess due to Fusobacterium nucleatum in a previously known case of Ebstein anomaly. A 44-year-old male presented with the complaints of headache, and fever. Cerebral imaging revealed parieto-occipital (PO) abscess. The abscess was drained and culture showed growth of Fusobacterium nucleatum. This report illustrates the importance of considering anaerobes as the cause of brain abscess, underscores the usefulness of MALDI, which facilitated the selection of appropriate and prompt adjuvant antibiotic therapy and a favourable outcome.


Subject(s)
Brain Abscess/diagnosis , Brain Abscess/etiology , Ebstein Anomaly/complications , Fusobacterium Infections/diagnosis , Fusobacterium Infections/etiology , Fusobacterium , Adult , Biomarkers , Brain/abnormalities , Brain/diagnostic imaging , Brain/pathology , Brain Abscess/therapy , Combined Modality Therapy , Embolism, Paradoxical/diagnosis , Embolism, Paradoxical/etiology , Fusobacterium Infections/therapy , Humans , Male , Tomography, X-Ray Computed , Treatment Outcome
3.
Neurol India ; 67(5): 1292-1302, 2019.
Article in English | MEDLINE | ID: mdl-31744962

ABSTRACT

BACKGROUND: Radiation-induced brain edema (RIBE) is a serious complication of radiation therapy. It may result in dramatic clinico-radiological deterioration. At present, there are no definite guidelines for management of the complication. Corticosteroids are the usual first line of treatment, which frequently fails to provide long-term efficacy in view of its adverse complication profile. Bevacizumab has been reported to show improvement in cases of steroid-resistant radiation injury. The objective of this study is to evaluate the role of Bevacizumab in post-radiosurgery RIBE. MATERIAL AND METHODS: Since 2012, 189 out of 1241 patients who underwent radiosurgery at our institution developed post-radiosurgery RIBE, 17 of which did not respond to high-dose corticosteroids. We systematically reviewed these 17 patients of various intracranial pathologies with clinic-radiological evidence of RIBE following gamma knife radiosurgery (GKRS). All patients received protocol-based Bevacizumab therapy. The peer-reviewed literature was evaluated. RESULTS: 82 percent of the patients showed improvement after starting Bevacizumab. The majority began to improve after the third cycle started improvement after the third cycle of Bevacizumab. Clinical improvement preceded radiological improvement by an average of eight weeks. The first dose was 5 mg/kg followed by 7.5-10 mg/kg at with two-week intervals. Bevacizumab needs to be administered for an average of seven cycles (range 5-27, median 7) for best response. Steroid therapy could be tapered in most patients by the first follow-up. One patient did not respond to Bevacizumab and needed surgical decompression for palliative care. One noncompliant patient died due to radiation injury. CONCLUSION: Bevacizumab is a effective and safe for treatment of RIBE after GKRS. A protocol-based dose schedule in addition to frequent clinical and radiological evaluations are required. Bevacizumab should be considered as an early treatment option for RIBE.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Bevacizumab/therapeutic use , Brain Edema/drug therapy , Radiation Injuries/drug therapy , Adult , Brain Edema/etiology , Female , Humans , Male , Middle Aged , Radiosurgery/adverse effects , Retrospective Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...